{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By NEIL UNMACK", "person": [{"firstname": "Neil", "rank": 1, "lastname": "UNMACK", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "425", "keywords": [{"rank": "1", "value": "Actelion Pharmaceuticals Ltd", "is_major": "N", "name": "organizations"}, {"rank": "2", "value": "Johnson & Johnson", "is_major": "N", "name": "organizations"}, {"rank": "3", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}], "lead_paragraph": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work.", "pub_date": "2016-11-25T21:22:24+0000", "document_type": "article", "source": "The New York Times", "snippet": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work....", "multimedia": [], "web_url": "http://www.nytimes.com/2016/11/25/business/dealbook/johnson-johnson-actelion.html", "slideshow_credits": null, "blog": [], "_id": "5838acd37c459f2525d0e5fb", "headline": {"main": "Johnson & Johnson Has Its Eye on Actelion", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}}